Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced the issuance of U.S. Patent No. 11,013,785, a foundational patent for novel therapeutic proteins, including KER-050. This patent is critical for Keros' wholly-owned internal programs and extends patent protection until at least November 2037. KER-050 is designed to treat cytopenias like anemia in patients with myelodysplastic syndromes and myelofibrosis. Keros plans to enhance its patent portfolio to support its expanding pipeline of hematological and musculoskeletal treatments.
Keros Therapeutics (Nasdaq: KROS) announced promising results from a preclinical study of KER-012 targeting pulmonary arterial hypertension (PAH) at the American Thoracic Society International Conference. The study demonstrated that KER-012 prevented markers of inflammation, fibrosis, and vascular remodeling in a rodent PAH model. Notably, the treatment reduced right ventricle and arterial wall thickness without increasing red blood cell counts, indicating potential for safe treatment of PAH. KER-012 could also enhance signaling pathways involved in bone disorders and PAH.
Keros Therapeutics (Nasdaq: KROS) announced the presentation of four abstracts from its KER-050 and ALK2 programs at the upcoming 26th Annual Congress of the European Hematology Association, taking place virtually from June 9-17, 2021. Findings include promising preclinical data on KER-050's ability to promote red blood cell production, relevant for conditions like myelodysplastic syndromes. The company is on track to report initial data from its Phase 2 clinical trial of KER-050 by the end of June 2021, solidifying its commitment to addressing hematological disorders.
Keros Therapeutics, Inc. (Nasdaq: KROS) reported a net loss of $15.9 million for Q1 2021, up from $11.9 million in Q1 2020, primarily due to increased research and development efforts. R&D expenses rose to $11.5 million, driven by activities related to KER-012 and higher personnel costs. General and administrative costs also increased to $4.3 million, reflecting organizational growth. Cash reserves stood at $255.2 million, expected to fund operations through Q4 2023. The company is advancing various clinical trials, including a Phase 2 trial of KER-050, with initial results anticipated mid-2021.
Keros Therapeutics (KROS) announced a business update and 2020 financial results, highlighting significant progress in clinical trials and a successful public offering. The fourth quarter net loss was $10.7 million, with a total loss of $45.4 million for the year, up from $12.3 million in 2019. R&D expenses totaled $9.7 million for Q4 and $33.9 million for 2020, reflecting increased activities. As of December 31, 2020, cash and equivalents stood at $265.9 million, securing operational funding into Q4 2023. Upcoming milestones include new trials for KER-050 and KER-047.
Keros Therapeutics (Nasdaq: KROS) presented preclinical results of KER-050 and its ALK2 inhibitor program at the ESH Translational Research E-Conference. The data supports a rapid hematological response and durable effects observed during Phase 1 trials, indicating potential for treating anemia due to ineffective erythropoiesis, particularly in myelodysplastic syndromes and myelofibrosis. Notable increases in red blood cells (7%) and hemoglobin (6.7%) were observed in mice after treatment with RKER-050, demonstrating promise in addressing hepcidin-mediated anemia and enhancing iron availability.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, Ph.D., present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference on March 9, 2021, starting at 7:00 am ET. The presentation will focus on Keros' advancements in treatments for hematological and musculoskeletal disorders. Investors can access the live presentation and subsequent replays for 90 days via the company’s website.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 1:40 PM ET. The presentation will be available via live webcast and archived for 90 days on Keros's website. Keros is focused on developing innovative treatments for hematological and musculoskeletal disorders, including KER-050 for cytopenias, KER-047 for iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced its addition to the NASDAQ Biotechnology Index, effective before market open on December 21, 2020. This index tracks biotechnology and pharmaceutical companies listed on Nasdaq. Keros specializes in developing treatments for hematological and musculoskeletal disorders, notably its lead candidates KER-050 for cytopenias and KER-047 for iron imbalance-related anemia. The company's work addresses significant unmet medical needs in these areas, showcasing its potential for growth and innovation in the biopharmaceutical sector.
Keros Therapeutics has appointed Mary Ann Gray, Ph.D., to its Board of Directors, enhancing its leadership team. Dr. Gray brings extensive experience from her roles in biotechnology and investment, including positions at Federated Kaufmann Fund and various biotech boards. Concurrently, Alon Lazarus will step down after serving since 2016. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with product candidates addressing conditions like cytopenias and bone loss.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
